南通江山农药化工股份有限公司 自 2024 年 1 月 1 日 至 2024 年 12 月 31 日止年度财务报表 KPMG Huazhen LLP 8th Floor, KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 Fax +86 (10) 8518 5111 Internet kpmg.com/cn 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街 1 号 东方广场毕马威大楼 8 层 邮政编码:100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 审计报告 毕马威华振审字第 2512151 号 南通江山农药化工股份有限公司全体股东： 一、审计意见 我们审计了后附的南通江山农药化工股份有限公司 (以下简称"江山股份公司") 财务报表， 包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并 及母公司现金流量表、合并及母公 ...

南通江山农药化工股份有限公司 于 2024 年 12 月 31 日 内部控制审计报告 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街1号 东方广场毕马威大楼8层 邮政编码:100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 内部控制审计报告 毕马威华振审字第 2512713 号 南通江山农药化工股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了南通 江山农药化工股份有限公司 (以下简称"江山股份") 2024 年 12 月 31 日的财务报告内部控制 的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指 引》的规定，建立健全和有效实施内部控制，并评价其有效性是江山股份董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见，并 对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能 ...

南通江山农药化工股份有限公司 2024 年度独立董事述职报告 作为南通江山农药化工股份有限公司的独立董事，本人严格按照《公司法》、 《证券法》、《上市公司独立董事管理办法》、《上海证券交易所股票上市规则》等 相关法律法规的要求，以及《公司章程》、《独立董事工作制度》的规定，本着独 立诚信、勤勉尽责的工作态度，按时出席公司股东大会、董事会及董事会各专门 委员会会议，慎重审议各项议案，全面关注公司的发展状况，忠实履行职责，充 分发挥独立董事的独立作用，切实维护了公司以及全体股东的合法权益。现将 2024 年度独立董事工作情况汇报如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 方国兵，男，1970年出生，武汉大学管理学博士，正高级会计师，注册会计 师 CPA，全国会计领军人才，上海市会计系列高级职称评审专家。曾任中国平安 人寿和中国人保寿险总公司财务部总经理、平安养老和平安陆金所财务总监 CFO， 中国大地保险首席风险官、财务总监 CFO 等。现任职于上海国家会计学院金融 系；同时兼任大智慧独立董事。2022年5月11日至今任本公司独立董事。 （二）独立性情况说明 作为公司的独立董事，本人 ...

（一）个人工作履历、专业背景以及兼职情况 周献慧，女，1955年出生，本科学历，高级工程师。1982年2月至1998年6 月任化工部计划司主任科员、副处长、处长；1998年7月至2000年3月任国家石化 局规划发展司综合处副处长(正处级)；2000年3月至2016年任中国石油化学工业 联合会(协会)副主任、主任、副秘书长；2015年6月至今任北京国化格瑞科技有 限公司执行董事、经理；2015年11月至今任中国化工环保协会理事长；同时兼任 丰山集团独立董事。2021年5月10日至今任本公司独立董事。 （二）独立性情况说明 南通江山农药化工股份有限公司 2024 年度独立董事述职报告 作为南通江山农药化工股份有限公司的独立董事，本人严格按照《公司法》、 《证券法》、《上市公司独立董事管理办法》、《上海证券交易所股票上市规则》等 相关法律法规的要求，以及《公司章程》、《独立董事工作制度》的规定，坚持客 观、公正、独立的原则，独立诚信、勤勉尽责，按时出席公司股东大会、董事会 及其专门委员会、独立董事专门会议，慎重审议各项议案，全面关注公司的发展 状况，忠实履行职责，充分发挥独立董事的独立作用，切实维护了公司以及全体 ...

南通江山农药化工股份有限公司 2024 年度独立董事述职报告 作为南通江山农药化工股份有限公司的独立董事，本人严格按照《公司法》、 《证券法》、《上市公司独立董事管理办法》、《上海证券交易所股票上市规则》等 相关法律法规的要求，以及《公司章程》、《独立董事工作制度》的规定，本着独 立诚信、勤勉尽责的工作态度，按时出席公司股东大会、董事会及董事会各专门 委员会会议，慎重审议各项议案，全面关注公司的发展状况，忠实履行职责，充 分发挥独立董事的独立作用，切实维护了公司以及全体股东的合法权益。现将 2024 年度独立董事工作情况汇报如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 张利军，男，1976年出生，大学学历，硕士学位，一级律师。现任江苏法德 东恒律师事务所执委会主席，兼任江苏省律师协会副会长、南京市人大常委会委 员、中国国际经济贸易仲裁委员会仲裁员，同时兼任江苏国信（002608）、协鑫 集成（002506）独立董事。2020年1月16日至今任公司独立董事。 （二）独立性情况说明 作为公司的独立董事，本人及配偶、父母、子女、主要社会关系均不在公司 或其附属企业任职、本人及配偶、父母、 ...

Dividend Distribution - The company plans to distribute a cash dividend of 1.00 CNY per 10 shares, totaling 43,065,000.00 CNY, which represents 19.19% of the net profit attributable to ordinary shareholders for the year [6]. - In the first half of 2024, the company distributed a cash dividend of 2.00 CNY per 10 shares, amounting to 86,130,000.00 CNY, accounting for 38.38% of the net profit attributable to ordinary shareholders [6]. - The total cash dividend for 2024 is projected to be 3.00 CNY per 10 shares, totaling 129,195,000.00 CNY, which constitutes 57.57% of the net profit attributable to ordinary shareholders [6]. - The company has maintained a focus on balancing long-term development and shareholder returns in its profit distribution policy [161]. - The company has not made any adjustments to its profit distribution policy during the reporting period [160]. Financial Performance - The company's operating revenue for 2024 was CNY 5,431,591,346.96, representing a 6.80% increase compared to CNY 5,085,696,347.20 in 2023 [23]. - The net profit attributable to shareholders for 2024 decreased by 20.69% to CNY 224,399,100.35 from CNY 282,952,031.26 in 2023 [23]. - The net cash flow from operating activities for 2024 was CNY 347,242,212.03, a decline of 54.90% compared to CNY 770,018,562.27 in 2023 [23]. - The basic earnings per share for 2024 was CNY 0.52, down 20.00% from CNY 0.65 in 2023 [24]. - The company achieved a weighted average return on equity of 6.09% in 2024, a decrease of 2.05 percentage points from 8.14% in 2023 [24]. Operational Efficiency - The production capacity utilization rate increased by 7.6 percentage points year-on-year, demonstrating improved operational efficiency [32]. - The company has a production capacity of 70,000 tons/year for glyphosate, making it one of the top four producers in China [39]. - The company has established a comprehensive risk prevention mechanism to enhance internal control effectiveness [33]. - The company has established a comprehensive governance structure and management system, enhancing operational efficiency [40]. Research and Development - The company applied for a record 63 patents during the year, indicating strong innovation efforts [32]. - The company is actively engaged in research on green and efficient pesticide processes and new flame retardants [32]. - The company invested a total of RMB 207.06 million in R&D, with 11 new projects initiated and 17 projects currently under research [85]. - The company completed 11 R&D projects in 2024, with 6 projects carried over to 2025 for continued development, including 17 high-end pesticide formulations approved for sale [85]. - The company is focusing on green and fine chemical technologies, achieving breakthroughs in continuous processes for hazardous operations like chlorination and nitration [86]. Environmental Protection - The company invested 1,341 million CNY in environmental protection during the reporting period [175]. - The company implemented over 30 environmental improvement projects, enhancing its waste treatment capabilities and significantly reducing pollutant discharge intensity [176]. - The company maintained a "green" dynamic environmental credit rating throughout the reporting period [176]. - The company’s subsidiaries reported stable pollutant discharge levels, meeting environmental standards with effective monitoring systems in place [177]. - The company’s overall environmental compliance is reflected in its adherence to the specified discharge limits for various pollutants [182]. Market Performance - The overseas sales revenue increased by over 30% year-on-year, reflecting effective marketing strategies [32]. - The company’s sales revenue for amide herbicides has been steadily increasing, with product quality leading in the domestic market [78]. - The global chemical crop protection market reached $74.806 billion in 2023, with a year-on-year growth of 0.1% [77]. - The global crop protection pesticide market is expected to reach $70.061 billion in 2024, a decrease of 6.4% compared to 2023, with the total pesticide market size at $77.195 billion, down 6.82% year-on-year [108]. Governance and Compliance - The company has established a governance structure that includes a board of directors, supervisory board, and management team to ensure clear responsibilities and independent operations [125]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements [126]. - The company has not faced any penalties from securities regulatory agencies in the past three years [141]. - The company has no significant discrepancies in governance compared to regulatory requirements, ensuring compliance with laws and regulations [128]. Human Resources - The company employed a total of 2,721 staff, with 1,682 in the parent company and 1,039 in major subsidiaries [154]. - The workforce includes 1,694 production personnel, 196 sales personnel, and 624 technical personnel [154]. - The company has established a standardized training system, linking training assessment results directly to employee job grading and promotion [157]. - The company introduced 22 key personnel through a market-oriented compensation mechanism during the reporting period [156]. Strategic Initiatives - The company plans to enhance its investment in R&D for genetically modified herbicides following recent policy changes in the agricultural sector [73]. - The company is positioned to benefit from the "Implementation Plan for the Innovation and Development of the Fine Chemical Industry" which supports mergers and acquisitions [74]. - The company plans to implement mergers and acquisitions to strengthen its core competitiveness and achieve high-quality development [113]. - The company aims to establish a technology barrier through new product and technology breakthroughs, promoting long-term development [86].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,745,960,034.77, representing a 10.15% increase compared to CNY 1,585,034,690.16 in the same period last year[4]. - Net profit attributable to shareholders increased by 89.10% to CNY 155,506,106.27 from CNY 82,236,390.36 year-on-year[4]. - The net profit after deducting non-recurring gains and losses rose by 88.29% to CNY 150,424,728.03 compared to CNY 79,890,658.15 in the previous year[4]. - Basic and diluted earnings per share increased by 89.47% to CNY 0.36 from CNY 0.19 in the same period last year[4]. - The weighted average return on equity improved by 1.84 percentage points to 4.10% from 2.26% year-on-year[4]. - Total revenue for Q1 2025 reached ¥1,745,960,034.77, an increase of 10.1% compared to ¥1,585,034,690.16 in Q1 2024[15]. - Net profit for Q1 2025 was ¥155,566,359.06, a significant increase of 83.1% compared to ¥84,985,087.54 in Q1 2024[16]. - Operating profit for Q1 2025 was ¥196,151,955.71, compared to ¥108,036,941.63 in Q1 2024, indicating a growth of 81.6%[16]. - The total comprehensive income attributable to the parent company was 153,275,316.53 RMB in the current period, compared to 82,353,024.64 RMB in the previous period, reflecting a year-over-year increase of approximately 86.1%[17]. - The company reported a total comprehensive income of 153,335,569.32 RMB for the current period, compared to 85,101,721.82 RMB for the previous period, indicating a strong performance improvement[17]. Cash Flow and Investments - The net cash flow from operating activities was negative at CNY -144,447,379.10, worsening by 111.25% compared to CNY -68,378,030.19 in the previous year[4]. - In Q1 2025, the company reported a net cash flow from operating activities of -144,447,379.10 RMB, compared to -68,378,030.19 RMB in Q1 2024, indicating a decline in operational cash flow[19]. - The company incurred total cash outflows from operating activities of 1,400,451,300.13 RMB in Q1 2025, slightly lower than 1,404,008,632.58 RMB in Q1 2024[20]. - The net cash flow from investing activities was -296,564,375.11 RMB in Q1 2025, compared to -171,726,834.48 RMB in Q1 2024, indicating increased investment expenditures[20]. - Cash flow from financing activities showed a significant increase, with a net inflow of 366,787,349.55 RMB in Q1 2025, compared to 23,878,873.62 RMB in Q1 2024[21]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 8,580,495,758.08, a slight decrease of 0.62% from CNY 8,633,606,390.28 at the end of the previous year[5]. - The company's total assets decreased to ¥8,580,495,758.08 from ¥8,633,606,390.28, a decline of 0.6%[12]. - Total liabilities decreased to ¥4,471,018,819.02 from ¥4,698,794,462.01, a reduction of 4.8%[13]. - The company's equity increased to ¥4,109,476,939.06 from ¥3,934,811,928.27, reflecting a growth of 4.4%[13]. - Shareholder equity attributable to the parent company increased by 4.12% to CNY 3,871,574,020.25 from CNY 3,718,441,923.98[5]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 21,841, with the largest shareholder holding 28.96% of the shares[8]. Research and Development - Research and development expenses for Q1 2025 were ¥49,625,232.21, slightly down from ¥49,970,406.04 in Q1 2024[16]. Other Income - The company reported non-recurring gains of CNY 5,081,378.24, primarily from government subsidies and other income[6]. - The company received tax refunds amounting to 51,059,429.46 RMB in Q1 2025, significantly higher than 14,072,381.92 RMB in Q1 2024[20]. - The company reported a financial income of ¥4,101,740.61 in Q1 2025, compared to ¥556,082.06 in Q1 2024, showing a substantial increase[16].

KPMG Huazhen LLP 8th Floor, KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 Fax +86 (10) 8518 5111 Internet kpmg.com/cn 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街 1 号 东方广场毕马威大楼 8 层 邮政编码:100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 关于南通江山农药化工股份有限公司 2024 年度非经营性资金占用及其他关联资金往来情况的专项说明 毕马威华振专字第 2502900 号 南通江山农药化工股份有限公司董事会： 我们接受委托，按照中国注册会计师审计准则审计了南通江山农药化工股份有限公司 (以 下简称"江山股份") 2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负 债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司 ...

南通江山农药化工股份有限公司 关于会计师事务所2024年度履职情况的评估报告 南通江山农药化工股份有限公司（以下简称"公司"）聘请毕马威华振会计师 事务所（特殊普通合伙）（以下简称"毕马威华振"） 作为公司 2024 年度年报审 计机构。根据财政部、国资委及证监会颁布的《国有企业、上市公司选聘会计师事 务所管理办法》，公司对毕马威华振在2024 年审计中的履职情况进行了评估。经评 估，公司认为，2024 年度毕马威华振资质等方面合规有效，履职能够保持独立性， 勤勉尽责，公允表达意见。具体情况如下： 一、资质条件 毕马威华振会计师事务所于1992年8月18日在北京成立，于2012年7月5日获财政 部批准转制为特殊普通合伙的合伙制企业，更名为毕马威华振会计师事务所（特殊 普通合伙），2012年7月10日取得工商营业执照，并于2012年8月1日正式运营。 毕马威华振总所位于北京，注册地址为北京市东城区东长安街1号东方广场东2 座办公楼8层。 毕马威华振的首席合伙人邹俊，中国国籍，具有中国注册会计师资格。 截至2024年12月31日，毕马威华振有合伙人241人，注册会计师1,309人，其中签 署过证券服务业务审计报告 ...

证券代码：600389 证券简称：江山股份 公告编号：临 2025-021 南通江山农药化工股份有限公司 2024 年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上市公司自律监管指引第 3 号行业信息披露：第十三 号—化工》、《关于做好主板上市公司 2024 年年度报告披露工作的重要提醒》的 要求，南通江山农药化工股份有限公司（以下简称"公司"）现将 2024 年度主要 经营数据披露如下： 注 1：上述产量含自用量、农药按含量折原药计算（下同）。 注 2：除草剂产品包括草甘膦、酰胺类等产品；杀虫剂产品包括敌百虫、敌敌畏等产品； 氯碱产品包括烧碱、盐酸、液氯、次氯酸钠等产品，其中烧碱产销量按 32%、48% 烧碱实物量计算（下同）。 注 3：阻燃剂（磷系）产品包含 TCPP、BDP 产品（下同）。 本报告之经营数据未经审计，公司董事会提醒投资者审慎使用上述数据。 特此公告。 南通江山农药化工股份有限公司董事会 2025 年 4 月 22 日 2 杀虫剂产品 27,071.74 27,1 ...